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Bronchial Thermoplasty –
Principles and Controversies
Pulmonary Grand Rounds
October 29, 2014
David R. Manoff, M.D

Objectives
• Learn the indications and contraindications for bronchial
thermoplasty
• Develop a basic understanding of the controversies about,
and the barriers to, the use of thermoplasty
• Understand the peri-procedural care and follow-up of
patients who receive bronchial thermoplasty

Conflicts of interest
• None

Our patient: a 54 year-old woman who presents with
difficult to control asthma
• Initially presented in April 2014 for evaluation for bronchial
thermoplasty
• Diagnosed 12 years prior to visit
• In year before presentation
• Three exacerbations requiring systemic corticosteroids
• Two hospitalizations for asthma exacerbations
• Five ED visits

• On Symbicort 160/4.5 HFA, Montelukast 10 mg PO daily, PRN
Albuterol HFA, which she uses daily
• Reports severe debility and unemployed for two months
since last hospitalization

• Past Medical History
• GERD
• Obstructive sleep apnea on CPAP 9 cm H2O

• Social History
• Lifetime non-smoker
• Lives in a house in process of being recarpeted
• Two birds (cockatiels), no other animals

• Physical exam unremarkable
• Spirometry
• FEV-1 2.81 liters (114% predicted)
• FVC 3.18 liters (106% predicted)
• FEV-1/FVC ratio 80%

Is the patient appropriate for proceeding
with bronchial thermoplasty

…but wait. What is bronchial thermoplasty really?
• Essentially, the application of radiofrequency to the proximal
airways to ablate smooth muscle
• Decrease airway hyperresponsiveness by decreasing the
ability of smooth muscle to constrict leading to decreased
resistance
• FDA approval for patients 18 years-old and older with
“severe and persistent asthma not well-controlled with
inhaled corticosteroids and long-acting beta agonists”

Iyer, VN, Lim, KG. Chest (2014); 146: 17-21.

What do the guidelines say?
• ATS/ERS Consensus on treatment of severe asthma

• “We recommend that bronchial thermoplasty is
performed in adults with severe asthma only in the
context of an Institutional Review Board-approved
independent systematic registry or a clinical study
(strong recommendation, very low quality evidence).”
• Why?
• Long term consequences unknown
• Invasive procedure
• Authors felt further characterization of subgroups needed
Chung, et al. Eur Resp J (2014); 43: 343-73.

The theory

• Based on recognition that airway smooth muscle contractility
leads to increased airway resistance and decreased diameter
• 11-dog study using a graded methacholine challenge both
pre-and-post RF ablation of proximal airways
• All thermoplasty was performed in a single procedure

Danek, CJ, et al. J Appl Physiol (2004); 97: 1946-53.

First human trials

• 9 patient prospective trial of patients scheduled to undergo
resection of known or suspected malignancy
• Thermoplasty only performed in areas of lung to be resected
• Tissue evaluated by histological examination after lung
tissue resected

Miller, JD, et al. Chest (2005); 127: 1999-2006.

• Again demonstrated minimal changes with RF ablation at 55O
C but more marked changes at 65O C
• Epithelium either normal (3/9 patients) or demonstrated
sloughing to regeneration
• Patient with shortest follow-up (5 days) had glandular
necrosis
• Non-infectious pneumonitis present in 27% of pathology
sections but no evidence of infectious pneumonitis
• Clinically, no post-procedural hemoptysis, infections,
additional clinic/ER visits, no need for additional
bronchodilators

First studies in asthmatics
• Cox (2006)
• 16 patient prospective study of patients with stable, mildmoderate asthma
• No changes to medications or symptoms in six weeks prior to study

• All patients pre-treated with corticosteroids
• Three sessions per patient, each three weeks apart
• One for each lower lobe
• One for bilateral upper lobes
• Right middle lobe not treated

• Follow-up with chest X-ray, EKG, methacholine challenge

Cox, G, et al. Am J Resp Crit Care Med (2006); 173: 965-9.

• Baseline pre-bronchodilator FEV1 maintained post-procedure
• For Methacholine PC20 means
•
•
•
•
•

Baseline 0.92 mg/mL
4.75 mg/mL at 12 weeks
5.45 mg/mL at 1 year
3.40 mg/mL at 2 years
At 12 weeks 5/16 patients did not
demonstrate a 20% decrease in
FEV-1 with 16 mg/mL of
methacholine

Moving to severe asthma – the AIR (1) Study – NEJM
2007
• Multicenter randomized control trial of ICS/LABA with or
without thermoplasty
• Adult patients with moderate-severe asthma
• Must be on high dose inhaled corticosteroid to achieve control
• Worsening of disease based on Asthma Control Questionnaire or
morning peak flows if LABA removed from treatment regimen
• All FEV-1s within 60-85% predicted
• Stable asthma in six weeks pre-treatment as previous

The AIR-2 Trial (2010)
• Large multi-center randomized, prospective trial for severe asthma
with bronchial thermoplasty vs. sham procedure
• Inclusion Criteria
•
•
•
•
•
•
•
•

Adults 18-65 requiring high-dose ICS and LABA
LTRAs, Omalizumab and low-dose (<10 mg/day) Prednisone allowed
Stable on therapy for four weeks
Baseline Asthma Quality of Life Questionnaire (AQLQ) score 6.25 or
lower (higher=better quality of life)
Pre-bronchodilator FEV-1 at least 60% predicted
Documented airway hyperresponsiveness (by methacholine
challenge)
Asthma symptoms at least two days per week
Non-smokers at least 1 year
Castro, M, et al. Am J Resp Crit Care Med (2010); 181: 116-124.

• Exclusion Criteria
•
•
•
•
•

Documented emphysema
Use of immunosuppressants, anticoagulants, or beta-blockers
3 or more hospital admissions for asthma
3 or more lower respiratory tract infections
4 or more pulse doses of oral steroids for exacerbations

• All patients had three bronchoscopies performed three
weeks apart; bronchoscopy team was unblinded
• Follow-up visit clinicians were blinded to group
• Patients evaluated at six weeks post-procedure then 3, 6, 9, 12month intervals

AIR-2 Outcomes

• Adverse Events
• During treatment, wheezing,
airway irritation, URIs common
• 8.4% of intervention group
required admission during
treatment phase (2% in sham
group)
• Worsening of asthma
• Lower respiratory tract infection
• Low post-procedural FEV-1

Okay, it looks like it works… Why all the controversy?
•
•
•
•

Was it really necessary?
Is it safe after the immediate post-procedure period?
Does it really work for severe asthma?
Is it cost-effective?

Long-term Follow-up of AIR-2
• Wechsler (2013)
• 162/190 post-bronchial thermoplasty patients from AIR-2 were
followed on a 3-month interval after the first year
• All patients maintained on controller medications
• Each patient monitored by spirometry, ED visits, asthma
exacerbations requiring steroids

Wechsler, ME, et al. J Allergy Clin Immunol (2013); 132: 1295-302.

• Controller therapy use
• At baseline 72% of patients were on two high-dose long-term
therapies (ICS+LABA) with 28% being on 3 or more medications
• At 5-year follow-up, 45/162 (28%) of patients to complete
follow-up had at least 50% decrease in medications
• 5/162 had increases in controller therapy

Long-Term Outcomes

Was it necessary?
• AIR-2 required patients with high-dose ICS and LABA therapy
to maintain symptom control
• Hawkins (BMJ 2003)
• 259 patient double-blinded RCT from Scotland of patients with
asthma on at least 800 mcg/day inhaled Beclomethasone
• Randomized to maintaining maintenance dose of ICS or
decreasing by 50%

Hawkins, G, et al. BMJ (2003); 326: 1115-21.

Will bronchial thermoplasty work for asthmatics with
fixed airway obstruction
• Maybe – No large scale trials
• Doening (2013)
• Eight-patient single center (University of Chicago) case series
• All had fixed airway obstruction and were on multiple controller
therapies
• Results
• At 15-week follow-up, no change in FEV-1 (p=0.4)
• No increase in hospitalization rate (mean 2.88 ± 1.2 vs. 0.5 ± 0.33)

Doening, et al. J Asthma (2013); 50: doi 10.3109/02770903.2012.751997

Pre-BD FEV1 (% predicted)
Pre-BD FEV1 <50%, n
ICS dose (mcg/day)
Other medications, n
LABA (≥100 mcg)
OCS
Leukotriene modifiers
Omalizumab
Methylxanthines
Anticholinergics
OCS dose (mg/day)
SABA use (puffs/day)
Avg. night wakings
(nights/week)
Hospitalizations last year
(total no.)
eNO (ppb)
IgE (IU/mL)

51.8 ± 8.6
5
1000
8
4
6
2
2
3
27.5 ± 4.8
6 ± 0.8
4.5 ± 1.0
23 ± 1.2
55 ± 17.4
155 ± 8.7

Overnight observations, n
Total no. of events
Total no. of patients with
an event
Cause, n
Increased BD use
Wheezing
Lower respiratory tract
infection
Atelectasis
Hemoptysis
Intubations, n
NIPPV, n
Deaths, n

11
5
5
2
2
1
1
0
0
0

Economics of Bronchial Thermoplasty
• Annual cost of asthma therapy is $3,300/patient (2002-2007)
• 59% of children and 33% of adults with asthma missed school
or work based on a 2008 study
• In spite of FDA approval in 2010, no private insurance
policies for coverage established
• CMS definition of “reasonable and necessary” unclear

• In 2007 (i.e. three years before AIR-2), multiple insurers had
non-coverage policies for BT labelling it experimental/
investigational
• Maintained after FDA approval
Mahajan, AK, Hogarth, K. Chest (2013); 144: 1051-4.

• Thermoplasty originally given Category 3 (experimental,
temporary) CPT codes
• Category 1 CPT codes for current medical practice, generally
recognized by all US insurers
• Category 1 CPT codes for BT now recognized as of January 2013
(codes 31660 and 31661)

• California Technology Assessment Forum panel 3/2012
• Third-party assessment agency for insurers
• Found that BT met safety and efficacy criteria for approval

• How much does thermoplasty cost to do?
• Alair thermoplasty system (one-time purchase): $60,000
• Alair thermoplasty catheters (one per procedure): $2,500
• Relief of symptoms: priceless

Is it potentially cost-saving?

• 5-year budget analysis model of the asthmatic population of
a district in Northern Italy
• Based on analysis of standard care with Omalizumab vs.
standard care and Omalizumab with the addition of
bronchial thermoplasty
• Demographics and patient numbers were estimated both on
ED visits, specialist visits, hospitalizations, and previous
population data
• Used 3.4% risk of severe adverse events per BT procedure
(based on AIR-2 data)
Menzella, F, et al. Adv Ther (2014); 31: 751-61.

Getting a patient approved for thermoplasty
• Almost every patient will require an appeal process
• Individual case review to establish necessity
• Must be able to demonstrate
• Diagnosis of asthma
• On therapy that constitutes best care
• Unable to achieve control of the disease with best control measures

• In 2011, 40% of appeals were approved on first request
• Increased to 60% in 2012

Mahajan, AK, Hogarth, K. Chest (2013); 144: 1051-4.

Bronchial Thermoplasty – Periprocedural care
• Pre-procedural protocol
• Patient given high-dose oral steroid (Prednisone 50 mg/day) for
1-3 days prior to the procedure, the day of procedure, and the
day after
• All patients should receive pre-procedural bronchodilator
therapy (2.5-5 mg Albuterol or 3 mL DuoNeb)
• Pre-procedural spirometry for baseline (no procedure if postbronchodilator FEV-1 <85% from baseline)
• No apparent URI symptoms

Mayse, ML, et al. J Bronchol (2007); 14: 115-23.

• Intraprocedure
• Can be done under moderate sedation or general anesthesia
• Both lower lobes done as separate procedures, upper lobes done
as third procedure
• If done under moderate sedation, liberal use of lidocaine at
vocal cords, trachea, airways to be treated
• Each segment is entered with the catheter and the array is
activated at 5 mm intervals distalproximal
• Oozing and secretions common, may require intraprocedural
cleaning of array

The thermoplasty procedure

Post-procedural monitoring
• All patients should be monitored for 4-6 hours postprocedure
• At three hours, patient should receive bronchodilator with
repeat spirometry being performed at hour 4 post-procedure
• Should not discharge if post-bronchodilator FEV-1 is <85% of
pre-procedural baseline
• Phone calls 1- and 3-days post-procedure
• Follow-up office visit 2-3 weeks post-procedure for
spirometry, assessment of symptoms, and to schedule next
step of procedure

Back to our patient
• First bronchial thermoplasty performed of right lower lobe
without immediate complication
• Did reqiure additional six days of Prednisone 40 mg/day
• At follow-up visit, reported mild improvement in asthma
symptoms

• After second thermoplasty (left lower lobe), patient
reported significant decrease in rescue Albuterol use
• After third thermoplasty, patient stated “I don’t think I still
have asthma anymore.” No longer carrying Albuterol inhaler
• Nocturnal awakenings monthly from 2-3/night

Conclusions
• Bronchial thermoplasty is a new, emerging technology for the
treatment of asthma which is difficult to control medically
• While no long-term studies exist, it has been demonstrated to be
safe at up to five years post-procedure
• There may be a cost-savings over usual care associated with
bronchial thermoplasty after the initial investment in the
procedure
• Bronchial thermoplasty is not a “cure-all” and patients will still
have residual symptoms. Careful patient selection is necessary to
ensure safety and success of the procedure
• Further studies are needed to determine the efficacy of the
procedure with fixed obstruction

Thank you!
Questions?

